# Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

> **NCT06141109** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xi'an Xintong Pharmaceutical Research Co.,Ltd.** · enrollment: 39 (estimated)

## Conditions studied

- Safety Issues
- Efficacy
- MTD

## Interventions

- **DRUG:** Sintilimab 200mg+MB07133 600mg

## Key facts

- **NCT ID:** NCT06141109
- **Lead sponsor:** Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-18
- **Primary completion:** 2024-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2023-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06141109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06141109, "Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06141109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*